Doravirine: its role in HIV treatment

Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents

(2021) Dathan M. Byonanebye   AIDS

Are New Antiretroviral Treatments Increasing the Risk of Weight Gain?

(2021) Shahini Shah et al.   DRUGS

Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial

(2021) Princy Kumar et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Cell culture selections reveal favourable drug resistance profiles for doravirine and islatravir

(2021) Bluma G Brenner et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa

(2021) Kim Steegen et al.   Journal of the International AIDS Society

The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations

(2020) Carlos Guerrero-Beltrán et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacokinetics of once-daily doravirine over 72 h following drug cessation

(2020) Xinzhu Wang et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Doravirine Use in Treatment-Experienced HIV-Positive Patients

(2020) Patricia Pecora Fulco et al.   ANNALS OF PHARMACOTHERAPY

Changes in weight and body mass index with first-line doravirine-based therapy

(2020) Orkin Chloe et al.   AIDS

Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug–Drug Interactions

(2020) Sauzanne Khalilieh et al.   CLINICAL DRUG INVESTIGATION

2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0

(2020) L Ryom et al.   HIV MEDICINE

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial

(2020) Chloe Orkin et al.   CLINICAL INFECTIOUS DISEASES

Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era

(2020) Stephanie A. Ruderman et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Doravirine and the Potential for CYP3A-Mediated Drug–Drug Interactions

(2019) Sauzanne G. Khalilieh et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Greater Weight Gain in Treatment Naïve Persons Starting Dolutegravir-Based Antiretroviral Therapy

(2019) Kassem Bourgi et al.   CLINICAL INFECTIOUS DISEASES

Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks

(2019) Margaret Johnson et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine

(2019) Alison Boyle et al.   CLINICAL PHARMACOKINETICS

Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment

(2019) Yali Wang et al.   Expert Opinion on Drug Metabolism & Toxicology

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naïve HIV-1 Infected Adults with Transmitted Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance Mutations

(2019) Alexander Wong et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

(2019) Paul E Sax et al.   CLINICAL INFECTIOUS DISEASES

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

(2019) Jean-Michel Molina et al.   Lancet HIV

Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy

(2019) Cathia Soulie et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics

(2018) Wendy Ankrom et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

OUP accepted manuscript

(2018)   CLINICAL INFECTIOUS DISEASES

Multiple Doses of Rifabutin Reduce Exposure of Doravirine in Healthy Subjects

(2018) Sauzanne G. Khalilieh et al.   JOURNAL OF CLINICAL PHARMACOLOGY

HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis

(2018) Ravindra K Gupta et al.   LANCET INFECTIOUS DISEASES

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

(2018) Jean-Michel Molina et al.   Lancet HIV

Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients

(2018) Cathia Soulie et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations

(2016) Meizhen Feng et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics

(2016) Sauzanne Khalilieh et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects

(2014) Matt S Anderson et al.   ANTIVIRAL THERAPY

In VitroCharacterization of MK-1439, a Novel HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor

(2013) Ming-Tain Lai et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses

(2013) Bernard Côté et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism

(2012) Kalyan Das et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY